Over the last two decades, the number of treatments being designed using RNA technology has been on the rise, although not widely recognized outside of scientific circles.
According to Informa Pharma Intelligence data, there has been a meteoric 182% rise in these treatments throughout the pandemic, paving the way for research and development of these therapies in other areas such as cancer or HIV.
Over half (50%) of respondents believe that COVID-19 has forced pharma companies to speed up their pace of innovation.